Compare Heron Therapeutics Inc (HRTX) vs Lumen Technologies Inc (LUMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Lumen Technologies Inc — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while Lumen Technologies Inc trades at $6.79 (market cap $6.47B). The key difference: Lumen Technologies Inc is far larger — about 70.7× Heron Therapeutics Inc's market cap, and Lumen Technologies Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | LUMN | |
|---|---|---|
Market Cap | $91.46M | $6.47B |
Sector | Health | Media |
52-Week High | $1.96 | $11.83 |
52-Week Low | $0.39 | $3.70 |
Enterprise Value | $189.36M | $18.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
LUMN trades at $6.275, down 0.08% on the day, with a bearish technical signal but oversold RSI readings. The company reported a net loss of $1.74B in 2025 despite beating EPS estimates in two of the last three quarters. Recent news highlights strategic acquisitions like Alkira to bolster its AI networking capabilities, while the balance sheet shows high debt levels of $17.49B long-term.
The outlook remains challenging due to persistent losses and heavy debt, though cost-cutting initiatives and a $13B contract backlog offer potential upside. Analyst consensus is cautious with a $8.25 price target, but the stock's deep value (P/S 0.52) may attract contrarians if EBITDA improves. Key risks include execution on turnaround plans and interest expense pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →
